NVAX Novavax Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVAX
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 21

EPS in 2026 (TTM): -$0.46

Last Report Period Date: Sep 30, 2026

As of November 2026, according to Novavax's latest financial report, the company's current EPS (TTM) is -$0.46. Novavax's EPS for 2025 came in at $2.72, marking an increase from -$1.23 in 2024. Novavax's earnings per share for the quarterly report ending on Sep 30, 2026 was -$0.19.

NVAX earnings history

Historical annual and quarterly earnings per share (EPS) data for Novavax
EPS (TTM)
-$0.46
EPS Growth YoY (Quarterly)
84.8%
EPS (Quarterly)
-$0.19
EPS Growth (Quarterly)
40.6%

The annual EPS in 2025 was $2.72, an increase of 321.1% from -$1.23 in 2024. The quarterly EPS for the period ending Sep 30, 2026, was -$0.19, marking a 84.8% increase from the same quarter last year. NVAX's TTM EPS stands at -$0.46 as of September 2026. Novavax's EPS for 2024 stood at -$1.23, a 77.3% increase from 2023.

NVAX EPS vs price chart

NVAX EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
84.8%
EPS growth YoY
321.1%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the last 12 months, Novavax has registered an EPS growth of 84.8% (YoY, quarterly).

NVAX Earnings Waterfall

Breakdown of revenue, profit and net income for Novavax

NVAX Earnings vs Peers

What are the earnings of NVAX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
AGEN Agenus Inc 10.25 100% N/A N/A
AZN Astrazeneca plc 25.89 45.4% 46% 22%
NVS Novartis AG 30.53 21.8% 31.2% 15.2%
PFE Pfizer Inc 40.7 -3.5% -37.4% -3.7%
SRPT Sarepta Therapeutics Inc 228.71 -388.7% N/A N/A
EBS Emergent Biosolutions Inc N/A 127.2% N/A -29.9%
BCRX Biocryst Pharmaceuticals Inc N/A 393% N/A N/A
NNVC Nanoviricides Inc N/A 34.9% N/A N/A
CLDX Celldex Therapeutics Inc N/A -59.2% N/A N/A
NVAX Novavax Inc N/A 321.1% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.